Condition
Polymorphic Post-Transplant Lymphoproliferative Disorder
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Rituximab
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT05786040Phase 2Recruiting
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
NCT02900976Phase 2Completed
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Showing all 2 trials
Research Network
Common Treatments
- Rituximab2
- Biopsy1
- Computed Tomography1
- Biospecimen Collection1
- Tafasitamab1
Active Sponsors
- Children's Oncology Group1
- National Cancer Institute (NCI)1
- Timothy Voorhees1
Top Investigators
Ohio State University Comprehensive Cancer Center
Children's Oncology Group
Related Conditions
- Monomorphic Posttransplant Lymphoproliferative Disorder1
- Recurrent Polymorphic Posttransplant Lymphoproliferative Disorder1
- Refractory Monomorphic Posttransplant Lymphoproliferative Disorder1
- Ebvrelated Posttransplant Lymphoproliferative Disorder1
- Recurrent Monomorphic Posttransplant Lymphoproliferative Disorder1